Dizajniranje sustava isporuke 5-fluorouracila u kolon tabletama obloženima miješanim filmom by RUCHITA V. KUMAR & VIVEK RANJAN SINHA
Colorectal cancer is the third most common cause of cancer deaths all over the
globe. The most extensively exploited formulation strategy for colon targeted drug de-
livery systems (CDDS) has been the employment of enteric coatings. The pH differential
in the different segments of the gastrointestinal tract is the basic triggering factor for pH-
-sensitive polymers. The release through these systems also depends on the transit time
of the formulation through the small intestine (1, 2). Thus, an optimized enteric coat is
desired for drug release in the colon. The site of drug release is tailored by modulating
the thickness of the coat (3). For the purpose of targeting drugs to the colon, the solid
dosage forms such as tablets, microparticulates, capsules and pellets are generally coa-
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The study was carried out to establish the effectiveness
of a mixed film composed of ethylcellulose/Eudragit
S100 for colonic delivery of 5-flourouracil (5-FU). Tablets
cores containing 5-FU were prepared by direct compres-
sion method by coating at different levels (2–9 %, m/m)
with a non-aqueous solution containing ethylcellulose/
Eudragit S100. Coated tablets were studied for the in vi-
tro release of 5-FU and the samples were analyzed spec-
trophotometrically at 266 nm. Drug release from coated
systems depended on the thickness of the mixed film
and the composition of the core. Channel formation was
initiated in the coat by dissolution of the Eudragit S100
fraction at higher pH in the colonic region. The release
was found to be higher in tablets containing Avicel as
filler owing to its wicking action compared to that from
lactose containing cores. Furthermore, batches contain-
ing superdisintegrant (1 %, m/m Cross-PVP) along with
Avicel in the core released approximately 81.1 % drug
during the colonic transit time. Kinetic studies indicated
that all the formulations followed first-order release kinet-
ics. The developed delivery system will expectedly de-
liver the drug to the colon.
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ted with a pH-sensitive polymer. These are the preferred pharmaceutical dosage forms
due to their relatively low cost of production and the ease of manufacture compared to
other more complex delivery systems (4). Much emphasis is currently being laid on the
development of mixed film coated systems, in which a combination of a release retar-
dant hydrophobic material and a hydrophilic material is employed to exploit the desired
benefits of each. The rationale behind adding a water-soluble fraction to the coat is to as-
sist in the generation of aqueous channels after a desired lag phase. These aqueous pores
help drug release in the colon. Various reports discussing the importance of the use of
polysaccharides as the desired hydrophilic pore formers have been published to date (5,
6). Wackerly and co-workers (7) have studied in detail the effect of mixed films com-
posed of ethylcellulose and pectin on the colonic delivery of paracetamol. As ethylcellu-
lose is a hydrophobic polymer, addition of a hydrophilic fraction to the coat results in
site-specific delivery of the drug through the aqueous pores formed by dissolution of
the pectin fraction of the film in the last segment of the GIT due to activity of pancreatic
enzymes.
The objective of the present study was to develop a novel mixed film coated system
composed of an appropriate combination of a hydrophobic polymer (e.g., ethylcellulose)
and an enteric polymer (e.g., Eudragit S100) to achieve maximal drug release in the prox-
imal segment of the colon. Considering the high applicability and usefulness of enteric
polymers in the development of CDDSs, an enteric polymer was selected as the pore for-
mer in the study. 5-Fluorouracil (5-FU) was chosen as the model drug. 5-FU is one of the
most widely used agents in the first-line chemotherapy of colorectal cancer (8). As 5-FU
is an extremely water soluble moiety, premature release of the drug in the upper segment
of the GIT is associated with many deleterious effects. Site-specific delivery of 5-FU to
the colon will also overcome the side-effects associated with the parenteral delivery of
the drug, which includes gastrointestinal toxicity, hematological and neural disorders
and cardiac manifestations (9). Furthermore, to achieve complete release of the drug
candidate at the site of action a small concentration of superdisintegrant (Cross-PVP) was
also introduced into the core (10). The influence of using various fillers, viz., spray dried
lactose and Avicel, was also studied.
EXPERIMENTAL
Preparation of 5-FU core tablets
Core tablets containing 250 mg of 5-FU were prepared by conventional direct com-
pression of the drug with different fillers, viz., spray dried lactose (SDL) and microcry-
stalline cellulose (Avicel PH102). Batches containing two different levels of Cross-PVP as
superdisintegrant were also prepared. Magnesium stearate (1 %) and talc (2 %) were
used as glidant and lubricant, respectively. Weighed quantities of excipients were thor-
oughly mixed with the drug by geometric addition in a mortar for about 10 minutes.
Pre-sieved magnesium stearate and talc were then added and further blended for 2 min-
utes. The homogeneous mixture thus obtained was weighed individually (350 mg) and
fed manually into the die of a single punch tablet machine (Modern Engineering, India)
equipped with 9.7-mm deep concave punches.
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Preparation of coating solution
The coating solution (6.0 %, m/V) containing ethylcellulose/Eudragit S100 in the
ratio 1:1 was prepared in a mixture of ethanol and isopropyl alcohol (1:3) using dibutyl
phthalate (10 %, m/m) as the plasticizer. The solution was stirred on a mechanical stirrer
for a sufficient period of time to obtain a clear solution.
Coating of the core tablets
All the batches were coated at different levels in the range from 2 to 9 %, m/m of the
initial tablet mass, using the pan coating method and dried with hot air with an inlet air
temperature of 35–45 °C. The coating process was continued in order to obtain the de-
sired level of coat mass. The percent coat mass gain (CMG) for all the bathes is given in
Table I.
In vitro release studies
To study the in vitro release profile of the drug, the dissolution test was carried out
on all the formulations according to the USP 27 (11) method for delayed release tablets
(method A). Dissolution studies were carried out using a USP apparatus type-II, i.e., pad-
dle type, at 50 rpm and at a temperature of 37 ± 0.5 °C. Initial studies were carried out in
750 mL of 0.1 mol L–1 HCl (pH 1.2) for 2 hours, followed by addition of 250 mL of 0.2
mol L–1 trisodium orthophosphate, in order to obtain a final pH of 6.8 in the medium.
Samples were withdrawn at predetermined time intervals and replaced with fresh me-
dia for 24 h. All the dissolution studies were performed in triplicate, i.e., three tablets
representative of each batch were studied. They were then analyzed using a UV-spectro-
photometer (Shimadzu-1601, Japan) at lmax of 266 nm.
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Table I. Composition of various batches
Batch code SDL (mg) Avicel PH102 (mg) Cross-PVP (mg) Coat mass gain (%)
MF1A 89.5 – – 1.8
MF1B 89.5 – – 3.9
MF1C 89.5 – – 5.3
MF2A – 89.5 – 2.2
MF2B – 89.5 – 4.0
MF2C – 89.5 – 6.2
MF3A – 86.0 3.5 1.7
MF3B – 86.0 3.5 5.8
MF3C – 86.0 3.5 8.4
*All the batches contained 250 mg of 5-FU and the final mass of each tablet was 350 mg.
Drug release kinetics
In order to study the mechanism of drug release from the prepared matrix tablets,
the release data obtained was evaluated using zero-order release kinetics (Eq. 1), first or-
der kinetics (Eq. 2), Higuchi’s square root of time equation (Eq. 3) (12), Korsemeyer and
Peppas equation (Eq. 4) (13) and Hixon-Crowell’s cube root of time equation (Eq. 5) (14).
Mt = M0 + k0t (1)
where Mt is the amount of drug dissolved in time t, M0 is the initial amount of drug in
the solution, k0 is the zero-order release rate constant and t is the release time,
Mt = M0e–kt (2)
where Mt is the amount of drug dissolved in time t, M0 is the initial amount of drug in
the solution, k is the first-order release rate constant and t is the release time,
Mt = kh t (3)
where Mt is the amount of drug dissolved in time t, kh is the Higuchi dissolution con-
stant and t is the release time,
Mt/M = ktn (4)
where, Mt and M are the cumulative amount of drug released at time t and infinite
time, respectively; ks is a constant incorporating structural and geometric characteristics
of the device, and n is the drug release exponent, indicative of the mechanism of drug
release. The values of n assigned to a cylinder are 0.45 for Fickian diffusion and 0.45 < n
< 0.89 for non-Fickian diffusion, respectively.
M01/3–Mt1/3 = kst (5)
where M0 is the initial amount of drug in the formulation, Mt is the amount remaining at
any time t and ks is the constant incorporating the surface-volume relation, in the Hi-
xon-Crowell model.
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The tablets showed good hardness (6–8 kg cm–2) and low friability (< 0.3 %). The
concentration of 5-FU in all the batches was 71.4 % (m/m). All the prepared batches
passed the uniformity of concentration test with 99.9 ± 0.6 % of absolute concentration.
Disintegration time of the coated tablets was recorded in phosphate buffer (pH 6.8). The
core tablets containing SDL disintegrated within 15 minutes; however the batches con-
taining MCC PH102 disintegrated into fragments within 5 minutes. This is attributed to
the fast wicking rate of MCC for water which aids in rapid disintegration of tablet for-
mulations (15). The uncoated tablet cores containing 1 % Cross-PVP disintegrated more
rapidly, within 2.75 minutes. However, the coated tablets remained intact when exposed
to disintegration studies for 2 h in 0.1 mol L–1 HCl followed by 1 h in phosphate buffer
(pH 8), indicating the effectiveness of the coat.
In vitro release
The in vitro release data obtained indicated that the rate of release of 5-FU is inver-
sely proportional to the thickness of the coat, suggesting that the film coat controls the
release process. The initial stage of drug release is probably due to the slow diffusion
through the ethylcellulose phase. The main reason proposed for the rise in drug release
after 6 h is the formation of aqueous pores in the film due to dissolution or the Eudragit
S100 fraction at an alkaline pH in the intestine. The core excipients used in the current
study also had a significant impact on the dissolution rate of the drug. Lack of drug re-
lease (i.e., < 4 % in 24 h) was observed in batches MF1A, B and C, containing SDL as
filler. The in vitro release profiles of batches MF2A, MF2B and MF2C containing Avicel
as filler indicated satisfactory results by preventing premature drug release in the initial
segment of the GIT to less than 2 % in the initial 6 h, followed by significant release in
the colon. The results for dissolution studies carried out on various formulations are shown
in Fig. 1a. This increase in 5-FU release in the last segment of the study is due to the for-
mation of a channel in the coat due to the dissolution of the Eudragit S100 fraction in the
alkaline microenvironment of the large intestine. Dissolution of this fraction of the film
generates pores which aid in the percolation of the media inside the core and dissolution
of the drug. Thus, after 10 h, 22.5 ± 0.1, 19.3 ± 1.1 and 2.9 ± 0.1 % of 5-FU was released
from batches MF2A, MF2B and MF2C, respectively. At the end of 24 h, approximately
47.2 ± 0.6, 34.6 ± 1.1 and 12.0 ± 0.4 % of the drug was released from batches MF2A, MF2B
and MF2C, respectively. Thus, MF2A formulation had a significantly higher release of
5-FU compared to all the other formulations tested. It was concluded that Avicel acted
as a disintegrating agent within these ethylcellulose/Eudragit-S100 film structures. Ow-
ing to its fast wicking rate for water, it aids in faster disintegration of tablet formulations
(16). However, in spite of the initial retardation, the Avicel cores were not able to release
the drug completely. To overcome this limitation and to achieve a complete release of
5-FU in the colonic region, a small amount of superdisintegrant was added to the core.
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Effect of superdisintegrant
Cross-PVP (1 %) was added as a superdisintegrant to the tablet core containing Avi-
cel as filler in order to increase drug release by rapid bursting of the tablet in the colonic
region. Tablets containing 1 %, m/V, Cross-PVP in the core were coated with a blend of
ethylcellulose/Eudragit-S100 (1:1) at three different levels (MF3A, MF3B and MF3C).
The cumulative percent release observed for the batches is shown in Fig. 1b. Optimum
release profile was obtained for batch MF3B, containing 1 % cross-PVP, Avicel and
coated with 5.8 % (m/V) of ethylcellulose/Eudragit S100 (1:1). This formulation showed
10.9 ± 7.6 % release in the initial 5 hours followed by approximately 80 % release during
the colon transit time, i.e., from 5 to 24 h. It was postulated that the pH-dependent disso-
lution of the Eudragit-S100 fraction generates pores in the film structure through which
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Fig. 1. Cumulative percent release of 5-fluorouracil coated at three levels with a mixture of ethyl-
cellulose/Eudragit-S100 (1:1) from: a) core tablets containing different fillers, viz., spray dried lac-
tose (MF1A-C) and Avicel (MF 2A-C) and b) from superdisintegrant containing core tablets coated at
three levels (MF 3A-C). Mean ± SD, n = 3.
the dissolution medium percolates into the core and interacts with the superdisintegrant
present in the core. The superdisintegrant has the tendency to absorb aqueous fluids
quickly, which results in bursting of the drug release from the tablet at latter time points.
This ensures complete drug release in the colonic segment of the GIT.
Kinetics of drug release
Values of the coefficient of determination for all the release models obtained are as
given in Table II. A comparative study of these values clearly showed that the first-order
model was the best-fit model for all the batches prepared during the study irrespective
of the nature of the filler or the presence or absence of the superdisintegrant. The values
of regression in the first-order model (i.e., R2) were close to unit in all cases. This is at-
tributed to the dissolution of the Eudragit S100 fraction of the film, which leads to the
formation of aqueous pores that facilitate drug dissolution proportional to the concen-
tration of the drug present in the core. Typically, all the water soluble drugs generally fol-
low the first-order release mechanism (17).
CONCLUSIONS
The present findings suggest that the developed mixed film coated system exploits
the benefits offered by both polymers used in the film. Both ethylcellulose and Eudragit
S100 synergistically prevent premature release of 5-FU owing to their hydrophobicity and
pH dependent solubility, respectively. The presence of Eudragit S100 simply accelerates
pore formation by dissolving in the alkaline pH and therefore enhancing release of 5-FU
in the colonic region. In addition, there is probably a significant contribution from the
superdisintegrant as the drug/excipient core gradually dissolves. The results of this study
have shown that ethylcellulose/Eudragit S100 combinations, when used as film coating
agents, may be valuable in colonic drug delivery.
349
R. V. Kumar and V. R. Sinha: Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system, Acta Pharm.
61 (2011) 343–351.
Table II. Comparative characteristics of different drug release models from various coated batches
Batch
code
R2 for release model
Zero-order First-order Higuchi Korsmeyer-Peppas Hixson-Crowell
MF1A 0.615 0.956 0.540 0.795 0.597
MF1B 0.615 0.993 0.511 0.880 0.845
MF1C 0.960 0.968 0.415 0.910 0.881
MF2A 0.912 0.951 0.474 0.814 0.740
MF2B 0.829 0.867 0.472 0.784 0.679
MF2C 0.980 0.987 0.452 0.647 0.816
MF3A 0.973 0.988 0.931 0.973 0.917
MF3B 0.922 0.997 0.696 0.892 0.790
MF3C 0.883 0.891 0.443 0.896 0.819
REFERENCES
1. R. Kinget, K. Willbrord, V. Liesbeth and G. Van den Mooter, Colonic drug targeting, J. Drug Tar-
get. 6 (1998) 129–149; DOI: 10.3109/10611869808997888.
2. C. S. Leopold and D. Eikeler, Basic coating polymers for the colon-specific drug delivery in inflam-
matory bowel disease, Drug Dev. Ind. Pharm. 26 (2000) 1239–1246; DOI: 10.1081/DDC-100102305.
3. T. Ishibashi, H. Hatano, M. Kobayashi, M. Mizone and M. Yoshino, Design and evaluation of a
new capsule-type dosage form for colon-targeted delivery of drugs, Int. J. Pharm. 168 (1998) 31–40;
DOI: 10.1016/S0378-5173(98)00082-9.
4. D. R. Friend, New oral delivery systems for treatment of inflammatory bowel disease, Adv. Drug
Del. Rev. 57 (2005) 247–265; DOI: 10.1016/j.addr.2004.08.011.
5. F. Li-Fang, H. Wei, B. Min, D. Qing, X. Bai, C. Yong-Zhen and C. De-Ying, Biphasic drug release:
permeability and swelling of pectin/ethyl cellulose films, and in vitro and in vivo correlation of
film-coated pellets in dogs, Chem. Pharm. Bull. 56 (2008) 1118–1125.
6. H. Wei, F. Li-Fan, B. Xiang, L. Chun-Lei, D. Qing, C. Yong-Zhen and C. De-Ying, An investiga-
tion into the characteristics of chitosan/Kollicoat SR30D free films for colonic drug delivery,
Eur. J. Pharm. Biopharm. 72 (2009) 266–274; DOI: 10.1016/j.ejpb.2008.10.017.
7. Z. Warkely, J. T. Fell, D. Attwood and D. Parkins, Pectin/ethyl cellulose film coating formula-
tion for colonic drug delivery, Pharm. Res. 13 (1996) 1210–1212; DOI: 10.1023/A:1016016404404.
8. G. D. Beretta, L. Milesi, M. A. Pessi, S. Mosconi and R. Labianca, Adjuvant treatment of colo-
rectal cancer, Surg. Oncol. 13 (2004) 63–73; DOI: 10.3322/canjclin.57.3.168.
9. K. Ciftci and M. J. Groves, Delivery of antitumor compounds to the rat colon: In vitro and in
vivo evaluation, Int. J. Pharm. 145 (1996) 157–164; DOI: 10.1016/S0378-5173(96)04764-3.
10. V. R. Sinha, J. R. Bhinge, R. Kumria and M. Kumar, Development of pulsatile systems for tar-
geted drug delivery of celecoxib for prophylaxis of colorectal cancer, Drug Deliv. 3 (2006) 221–225;
DOI: 10.1080/10717540500309180.
11. United States Pharmacopoeia XXXII, National Formulary XXVII, Asian Edition USP, Convention,
Rockville (M. D.) Volume 1, 2009. p. 263.
12. T. Higuchi, Rate of release of medications from ointment bases containing drugs in suspension,
J. Pharm. Sci. 50 (1961) 874–875; DOI: 10.1002/jps.2600501018/pdf.
13. R. W. Korsemeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms of potasssiun
chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air,
J. Pharm. Sci. 72 (1983) 1189–1191. DOI: 10.1002/jps.2600721021.
14. A. W. Hixon and J. H. Crowell, Dependence of reaction velocity upon surface and agitation, Ind.
Eng. Chem. 23 (1931) 923–931; DOI: 10.1021/ie50260a018.
15. Y. X. Bi, H. Sunada, Y. Yonezawa and K. Danjo, Evaluation of rapidly disintegrating tablets pre-
pared by direct compression method, Drug Dev. Ind. Pharm. 25 (1999) 571–581; DOI: 10.1081/
DDC-100102211.
16. M. Jivraj, L. G. Martini and C. M. Thomson, An overview of the different excipients useful for
the direct compression of tablets, Pharm. Sci. Tech. Today 3 (2000) 58–63; DOI: 10.1016/S1461-
-5347 (99)00237-0.
17. S. Risk, D. Duru, D. Gaudy and M. Jacob, Natural polymer hydrophilic matrix: influencing drug
release factors, Drug Dev. Ind. Pharm. 16 (1994) 2563–2574; DOI: 10.3109/03639049409042660.
350
R. V. Kumar and V. R. Sinha: Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system, Acta Pharm.
61 (2011) 343–351.
S A @ E T A K
Dizajniranje sustava isporuke 5-fluorouracila u kolon tabletama
oblo`enima mije{anim filmom
RUCHITA V. KUMAR i VIVEK RANJAN SINHA
Cilj rada bio je pripraviti mije{ane filmove od etilceluloze i Eudragita S100 za ispo-
ruku 5-flourouracil (5-FU) u kolon. Jezgre tableta s 5-FU pripravljene su metodom izrav-
ne kompresije koriste}i nevodenu otopinu etilceluloze/Eudragita S100 (2–9 %, m/m). Iz
oblo`enih tableta prou~avano je in vitro osloba|anje 5-FU koriste}i spektrofotometrijsku
analizu na 266 nm. Osloba|anje lijeka iz oblo`enog sustava ovisilo je o debljini filma i
sastavu jezgre tablete. Stvaranje kanala u ovojnici potaknuto je otapanjem frakcije s Eu-
dragitom S 100 pri vi{em pH u debelom crijevu. Ja~e osloba|anje bilo je iz tableta s Avi-
celom kao punilom nego iz tableta s laktozom zahvaljuju}i kapilarnom djelovanju Avi-
cela. Nadalje, pripravci sa superdezintegratorom (1 %, m/m Cross-PVP) i Avicelom oslo-
ba|ali su pribli`no 81,1 % lijeka u vremenu koje je potrebno za prolaz tableta kroz kolon.
Kineti~ka ispitivanja pokazuju da svi pripravci slijede kinetiku prvog reda. Razvijeni
sustavi trebali bi biti pogodni za isporuku lijeka u kolon.
Klju~ne rije~i: 5-flourouracil, etilceluloza, Eudragit-S100, krospolivinilpirolidon, laktoza, Avicel
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